Please use this identifier to cite or link to this item:
https://www.arca.fiocruz.br/handle/icict/35972
Type
ArticleCopyright
Open access
Sustainable Development Goals
03 Saúde e Bem-EstarCollections
Metadata
Show full item record49
CITATIONS
49
Total citations
15
Recent citations
4.6
Field Citation Ratio
2.54
Relative Citation Ratio
CIRCULATING MIRNAS AS POTENTIAL BIOMARKERS ASSOCIATED WITH CARDIAC REMODELING AND FIBROSIS IN CHAGAS DISEASE CARDIOMYOPATHY
Author
Nonaka, Carolina Kymie Vasques
Macêdo, Carolina Thé
Cavalcante, Bruno Raphael Ribeiro
Alcântara, Adriano Costa de
Silva, Daniela Nascimento
Bezerra, Milena da Rocha
Caria, Alex Cleber Improta
Tavora, Fábio Rocha Fernandes
Souza Neto, João David de
Rabelo, Márcia Maria Noya
Rogatto, Silvia Regina
Santos, Ricardo Ribeiro dos
Souza, Bruno Solano de Freitas
Soares, Milena Botelho Pereira
Macêdo, Carolina Thé
Cavalcante, Bruno Raphael Ribeiro
Alcântara, Adriano Costa de
Silva, Daniela Nascimento
Bezerra, Milena da Rocha
Caria, Alex Cleber Improta
Tavora, Fábio Rocha Fernandes
Souza Neto, João David de
Rabelo, Márcia Maria Noya
Rogatto, Silvia Regina
Santos, Ricardo Ribeiro dos
Souza, Bruno Solano de Freitas
Soares, Milena Botelho Pereira
Affilliation
Hospital São Rafael. Centro de Biotecnologia e Terapia Celular. Salvador, BA, Brasil / Fundação Oswaldo Cruz. Instituto Gonçalo Moniz. Salvador, BA, Brasil / D’Or Institute for Research and Education. Rio de Janeiro, RJ, Brazil.
Fundação Oswaldo Cruz. Instituto Gonçalo Moniz. Salvador, BA, Brasil / São Rafael Hospital. Department of Cardiology. Salvador, BA, Brasil.
Hospital São Rafael. Centro de Biotecnologia e Terapia Celular. Salvador, BA, Brasil / Fundação Oswaldo Cruz. Instituto Gonçalo Moniz. Salvador, BA, Brasil / D’Or Institute for Research and Education. Rio de Janeiro, RJ, Brazil.
Hospital São Rafael. Centro de Biotecnologia e Terapia Celular. Salvador, BA, Brasil.
Hospital São Rafael. Centro de Biotecnologia e Terapia Celular. Salvador, BA, Brasil / Fundação Oswaldo Cruz. Instituto Gonçalo Moniz. Salvador, BA, Brasil / D’Or Institute for Research and Education. Rio de Janeiro, RJ, Brazil.
Hospital São Rafael. Centro de Biotecnologia e Terapia Celular. Salvador, BA, Brasil.
Hospital São Rafael. Centro de Biotecnologia e Terapia Celular. Salvador, BA, Brasil / Universidade Federal da Bahia. Salvador, BA, Brasil.
Messejana Hospital. Fortaleza, CE, Brasil.
Messejana Hospital. Fortaleza, CE, Brasil.
São Rafael Hospital. Department of Cardiology. Salvador, BA, Brasil.
University of Southern Denmark. Institute of Regional Health Research. Vejle Hospital. Department of Clinical Genetics. Vejle, Denmark.
Fundação Oswaldo Cruz. Instituto Gonçalo Moniz. Salvador, BA, Brasil / National Institute of Science and Technology for Regenerative Medicine. Rio de Janeiro, RJ, Brazil.
Salvador, BA, Brasil / D’Or Institute for Research and Education. Rio de Janeiro, RJ, Brazil / National Institute of Science and Technology for Regenerative Medicine. Rio de Janeiro, RJ, Brazil.
Fundação Oswaldo Cruz. Instituto Gonçalo Moniz. Salvador, BA, Brasil / National Institute of Science and Technology for Regenerative Medicine. Rio de Janeiro, RJ, Brazil.
Fundação Oswaldo Cruz. Instituto Gonçalo Moniz. Salvador, BA, Brasil / São Rafael Hospital. Department of Cardiology. Salvador, BA, Brasil.
Hospital São Rafael. Centro de Biotecnologia e Terapia Celular. Salvador, BA, Brasil / Fundação Oswaldo Cruz. Instituto Gonçalo Moniz. Salvador, BA, Brasil / D’Or Institute for Research and Education. Rio de Janeiro, RJ, Brazil.
Hospital São Rafael. Centro de Biotecnologia e Terapia Celular. Salvador, BA, Brasil.
Hospital São Rafael. Centro de Biotecnologia e Terapia Celular. Salvador, BA, Brasil / Fundação Oswaldo Cruz. Instituto Gonçalo Moniz. Salvador, BA, Brasil / D’Or Institute for Research and Education. Rio de Janeiro, RJ, Brazil.
Hospital São Rafael. Centro de Biotecnologia e Terapia Celular. Salvador, BA, Brasil.
Hospital São Rafael. Centro de Biotecnologia e Terapia Celular. Salvador, BA, Brasil / Universidade Federal da Bahia. Salvador, BA, Brasil.
Messejana Hospital. Fortaleza, CE, Brasil.
Messejana Hospital. Fortaleza, CE, Brasil.
São Rafael Hospital. Department of Cardiology. Salvador, BA, Brasil.
University of Southern Denmark. Institute of Regional Health Research. Vejle Hospital. Department of Clinical Genetics. Vejle, Denmark.
Fundação Oswaldo Cruz. Instituto Gonçalo Moniz. Salvador, BA, Brasil / National Institute of Science and Technology for Regenerative Medicine. Rio de Janeiro, RJ, Brazil.
Salvador, BA, Brasil / D’Or Institute for Research and Education. Rio de Janeiro, RJ, Brazil / National Institute of Science and Technology for Regenerative Medicine. Rio de Janeiro, RJ, Brazil.
Fundação Oswaldo Cruz. Instituto Gonçalo Moniz. Salvador, BA, Brasil / National Institute of Science and Technology for Regenerative Medicine. Rio de Janeiro, RJ, Brazil.
Abstract
Chagas disease (CD) affects approximately 6-7 million people worldwide, from which 30% develop chronic Chagas cardiomyopathy (CCC), usually after being asymptomatic for years. Currently available diagnostic methods are capable of adequately identifying infected patients, but do not provide information regarding the individual risk of developing the most severe form of the disease. The identification of biomarkers that predict the progression from asymptomatic or indeterminate form to CCC, may guide early implementation of pharmacological therapy. Here, six circulating microRNAs (miR-19a-3p, miR-21-5p, miR-29b-3p, miR-30a-5p, miR-199b-5p and miR-208a-3p) were evaluated and compared among patients with CCC (n = 28), CD indeterminate form (n = 10) and healthy controls (n = 10). MiR-19a-3p, miR-21-5p, and miR-29b-3p were differentially expressed in CCC patients when compared to indeterminate form, showing a positive correlation with cardiac dysfunction, functional class, and fibrosis, and a negative correlation with ejection fraction and left ventricular strain. Cardiac tissue analysis confirmed increased expression of microRNAs in CCC patients. In vitro studies using human cells indicated the involvement of these microRNAs in the processes of cardiac hypertrophy and fibrosis. Our study suggests that miRNAs are involved in the process of cardiac fibrosis and remodeling presented in CD and indicate a group of miRNAs as potential biomarkers of disease progression in CCC.
Share